Advances in antiviral vaccine development.
Advances in antiviral vaccine development.
复制标题
DOI：
10.1111/imr.12098
复制
发表时间：
2013-09
影响因子：
8.7
通讯作者：
Graham BS
中科院分区：
文献类型：
--
作者：
Graham BS
抗病毒疫苗是预防流行性病毒性疾病最成功的生物医学干预措施。人类天花和牛牛瘟疫苗接种是根除疾病的基础，最近在根除小儿麻痹症方面取得的进展很有希望。虽然早期的疫苗是通过在活动物或鸡蛋中传代而凭经验开发的，但由于新技术的出现，特别是细胞培养和分子生物学，已经开发了更近期的疫苗。基因递送和表达、纳米颗粒、蛋白质制造和佐剂方面的最新技术进步为新的疫苗平台创造了潜力，这些疫苗平台可能为针对目前不存在干预措施的病毒病原体的疫苗提供解决方案。此外，人类单克隆抗体分离、结构生物学和高通量测序的技术融合为原子水平的免疫原设计提供了新的机会。选择人单克隆抗体可以鉴定与中和相关的免疫显性抗原位点，并提供用于稳定和解决病毒表面蛋白结构的试剂。了解中和的结构基础可以指导疫苗靶点的选择。抗体库的深度测序和定义所需抗体应答的个体发生可以揭示B细胞识别和亲和力成熟的连接重组和体细胞突变要求。总的来说，这些信息将为选择疫苗抗原、制剂和方案提供新的战略方法。此外，它为合理的疫苗设计和建立疫苗技术平台目录创造了潜力，这些平台将有效对抗任何特定家族或类别的病毒病原体，并提高我们应对新出现的病毒威胁的准备程度。
Antiviral vaccines have been the most successful biomedical intervention for preventing epidemic viral disease. Vaccination for smallpox in humans and rinderpest in cattle was the basis for disease eradication, and recent progress in polio eradication is promising. While early vaccines were developed empirically by passage in live animals or eggs, more recent vaccines have been developed because of the advent of new technologies, particularly cell culture and molecular biology. Recent technological advances in gene delivery and expression, nanoparticles, protein manufacturing, and adjuvants have created the potential for new vaccine platforms that may provide solutions for vaccines against viral pathogens for which no interventions currently exist. In addition, the technological convergence of human monoclonal antibody isolation, structural biology, and high throughput sequencing is providing new opportunities for atomic-level immunogen design. Selection of human monoclonal antibodies can identify immunodominant antigenic sites associated with neutralization and provide reagents for stabilizing and solving the structure of viral surface proteins. Understanding the structural basis for neutralization can guide selection of vaccine targets. Deep sequencing of the antibody repertoire and defining the ontogeny of the desired antibody responses can reveal the junctional recombination and somatic mutation requirements for B-cell recognition and affinity maturation. Collectively, this information will provide new strategic approaches for selecting vaccine antigens, formulations, and regimens. Moreover, it creates the potential for rational vaccine design and establishing a catalogue of vaccine technology platforms that would be effective against any given family or class of viral pathogens and improve our readiness to address new emerging viral threats.
登录
查看更多内容
影响因子：
6.4
作者：
GRAHAM, BS;GORSE, GJ;SMITH, GE
通讯作者：
SMITH, GE
影响因子：
56.9
作者：
Altman, JD;Moss, PAH;Davis, MM
通讯作者：
Davis, MM
HIV-1 疫苗功效试验的免疫相关分析。
DOI：
10.1056/nejmoa1113425
发表时间：
2012-04-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
Haynes BF;Gilbert PB;McElrath MJ;Zolla-Pazner S;Tomaras GD;Alam SM;Evans DT;Montefiori DC;Karnasuta C;Sutthent R;Liao HX;DeVico AL;Lewis GK;Williams C;Pinter A;Fong Y;Janes H;DeCamp A;Huang Y;Rao M;Billings E;Karasavvas N;Robb ML;Ngauy V;de Souza MS;Paris R;Ferrari G;Bailer RT;Soderberg KA;Andrews C;Berman PW;Frahm N;De Rosa SC;Alpert MD;Yates NL;Shen X;Koup RA;Pitisuttithum P;Kaewkungwal J;Nitayaphan S;Rerks-Ngarm S;Michael NL;Kim JH
通讯作者：
Kim JH
DOI：
10.1073/pnas.90.5.1882
发表时间：
1993-03-01
影响因子：
11.1
作者：
COONEY, EL;MCELRATH, MJ;GREENBERG, PD
通讯作者：
GREENBERG, PD
影响因子：
6.4
作者：
GRAHAM, BS;MATTHEWS, TJ;KOFF, WC
通讯作者：
KOFF, WC